FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple
This article was originally published in Pharmaceutical Approvals Monthly
Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP
You may also be interested in...
Advisory committee proposes a 10% non-inferiority margin for community-acquired pneumonia drugs. The Anti- Infective Drugs panel agreed that it is possible to establish a treatment effect for comparator agents based on incomplete data from original placebocontrolled CAP trials of the early 1900s. However, the group was divided over whether there is a basis for evaluating endpoints other than mortality. There was consensus that placebo-controlled trials are inappropriate for any severity of CAP
FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs